Jiang et al. demonstrated that SAA1 was increased in the NAFLD liver in both humans and mice, and SAA1/1 deficiency alleviated HFD‐induced metabolic disorder, hepatic steatosis and inflammation. This evidence concerns the gene SAA1 and Hepatic steatosis.